CYP Genetic Variants, CYP Metabolite Levels, and Symptomatic Carotid Stenosis in Ischemic Stroke Patients

Xingyang Yi¹, Duanxiu Liao¹, Lang Wu², Hong Chen¹, Jie Li¹ and Chun Wang¹

¹Department of Neurology, The People’s Hospital of Deyang City, Sichuan, China
²Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt University School of Medicine, Tennessee, USA

Aim: To evaluate the relationship between CYP genetic polymorphisms and CYP metabolite levels with carotid artery stenosis in acute ischemic stroke (IS) patients.

Methods: Eleven single nucleotide polymorphisms (SNPs) of seven CYP genes were genotyped in 136 IS patients with carotid stenosis and 158 patients without carotid stenosis. CYP plasma metabolite levels [20-hydroxyeicosatetraenoic acid (HETE), total epoxyeicosatrienoic acids (EETs), and dihydroxyeicosatrienoic acids (DiHETEs)] were assessed in a subsample of 90 patients with carotid stenosis and 96 patients without carotid stenosis. We evaluated the relationship between assessed variants and carotid stenosis risk, variants with CYP metabolite levels, and variants in mediating the differences of CYP metabolite levels between patients with carotid stenosis and those without. Additionally, gene–gene interactions were analyzed to assess the interactive role of the assessed variants in affecting CYP metabolite levels and risk of carotid stenosis.

Results: The genotypes of rs17110453CC, rs751141GG, and rs9333025GG were significantly associated with carotid stenosis risk. Also these polymorphisms were associated with CYP plasma metabolite levels in patients with carotid stenosis. There was a significant gene–gene interaction between rs17110453 and rs9333025 in affecting the risk of carotid stenosis. Patients with rs17110453CC and rs9333025GG had a significantly higher risk of carotid stenosis than those with rs17110453AA and rs9333025AA (OR = 2.12, 95% CI: 1.13–7.26, P = 0.013).

Conclusions: Specific CYP450 gene SNPs and their interactions are associated with CYP450 plasma metabolite levels, which may partially explain their associations with carotid stenosis. Further studies are needed to validate our findings.

J Atheroscler Thromb, 2016; 23: 621-631.

Key words: Carotid atherosclerosis, Carotid stenosis, Cytochrome P450, Single nucleotide polymorphisms, GMDR
influencing the risk of carotid stenosis can provide valuable insights into the pathogenesis of this disease, which can have implications for preventing stroke and stroke recurrence. However, to date such a genetic etiology has not been satisfactorily understood.

Genes involved in inflammation and endothelial function have been suggested to be involved in the pathogenesis of atherosclerosis. Arachidonic acid (AA) and metabolites of 20-hydroxyeicosatetraenoic acid (20-HETE) and epoxyeicosatrienoic acids (EETs) have inflammatory activities. AA can be metabolized by CYP ω-hydroxylase into 20-HETE or by CYP epoxygenases into four EETs, which can then be metabolized by soluble epoxide hydrolase (sEH) to yield less biologically active dihydroxyeicosatrienoic acids (DiHETEs). A study has suggested an association between these metabolite levels with stroke risk. However, till date few studies have assessed the association between these AA metabolites and carotid artery stenosis. To evaluate such a relationship is critical for understanding the etiology of carotid stenosis within the context of stroke.

Several genes have been involved in the AA metabolism pathway. For example, CYP4A11 and CYP4F2 genes encode CYP ω-hydroxylase; the CYP 2, 3 gene family encodes majority of epoxygenase enzymes; and the epoxide hydrolase-2 (EPHX2) gene encodes sEH. Some studies have shown that genetic variants of relevant genes are associated with their metabolite levels, an increased blood pressure, and a higher risk of stroke. However, few studies have assessed the relationship between these genetic variants, CYP metabolite levels, and the risk of carotid stenosis in stroke patients.

Aim

There was a significant association of carotid stenosis with stroke recurrence and cardiovascular outcomes after IS. It is critical to further understand the risk of carotid stenosis in the context of stroke, including the genetic etiology, for developing further strategies for preventing stroke and stroke recurrence. Therefore, the aim of the present study was to evaluate whether CYP gene polymorphisms and their plasma metabolite levels are associated with severe carotid artery stenosis in patients with IS. We also assessed potential gene–gene interaction effects in modulating the associations.

Materials and Methods

Study Population

In the current study, we studied 136 consecutive acute IS patients with significant (≥50%) symptomatic carotid stenosis and 158 acute IS patients with no carotid stenosis using carotid ultrasound examination. These subjects suffered from first IS stroke, were admitted within 3 days of the index stroke onset, and received medical care in the People’s Hospital of Deyang City between August 2011 and March 2013. The diagnosis of IS was confirmed on the basis of both clinical findings and neurological examinations using computerized tomography or magnetic resonance imaging. Patients were defined as with symptomatic carotid artery stenosis if they experienced an ipsilateral (carotid territory) IS. Exclusion criteria included: (i) patients with atrial fibrillation or other cardiac sources of emboli; (ii) IS caused by unknown factors; (iii) asymptomatic carotid artery stenosis; (iv) patients that are biologically related to each other.

Patients without carotid stenosis were selected from consecutive IS patients during the same time period (between August 2011 and March 2013). Patients without carotid stenosis were defined as no carotid stenosis (<15% stenosis). Exclusion criteria included: (i) symptomatic or asymptomatic carotid stenosis (≥50%); (ii) patients with 15%−49% stenosis; (iii) patients with atrial fibrillation or other cardiac sources of emboli; (iv) IS caused by unknown factors; (v) any relatedness between IS patients.

Standard Protocol Approvals, Registrations, and Patient Consents

The protocol of this study was reviewed and approved by the Ethics Committee of The People’s Hospital of Deyang City. All patients provided written informed consent before enrollment into this study.

Echocardiography and Holter monitoring examinations were performed on all patients. Vascular risk factors including body mass index (BMI), tobacco smoking history, diabetes mellitus, and hypertension were collected. Fasting blood samples were collected for assessing blood sugar, total plasma cholesterol (TC), triglycerides (TG), and low-density lipoprotein cholesterol (LDL-C).

Carotid Ultrasonography

We performed duplex scans in duplicate with the equipment of Acuson Sequoia Apparatus type 512 (7.5-MHz probe, Berlin, Germany). The degree of stenosis was evaluated using color duplex imaging and power mode, for both longitudinal and transverse sections. The morphological lumen reduction assessment in diameter was combined with peak systolic velocities at the location of the stenosis as well as the internal carotid artery/common carotid artery ratio. The fol-
Table 1. Characteristics of ischemic stroke patients with or without carotid stenosis

| Characteristics                  | Carotid stenosis (n = 136) | Non-carotid stenosis (n = 158) | P value |
|----------------------------------|-----------------------------|--------------------------------|---------|
| Age (years)                      | 68.86±12.23                 | 67.98±11.82                    | 0.618   |
| Men (n, %)                       | 82 (60.29)                  | 93 (58.86)                     | 0.592   |
| Diabetes mellitus (n, %)         | 47 (34.56)                  | 52 (32.91)                     | 0.487   |
| Hypertension (n, %)              | 110 (80.88)                 | 127 (80.38)                    | 0.998   |
| Previous MI (n, %)               | 2 (1.47)                    | 3 (1.89)                       | 0.992   |
| Previous angina pectoris         | 3 (2.21)                    | 3 (1.89)                       | 0.982   |
| Cigarette smoking (n, %)         | 55 (40.44)                  | 62 (39.24)                     | 0.942   |
| Body mass index (kg/m²)          | 24.08±2.36                  | 23.95±2.56                     | 0.926   |
| Rates of dyslipidemia (n, %)     | 75 (55.15)                  | 80 (50.63)                     | 0.473   |
| TC (mM)                          | 5.76±1.56                   | 5.62±1.32                      | 0.786   |
| LDL-C (mM)                       | 3.15±1.27                   | 2.99±1.19                      | 0.475   |
| HDL-C (mM)                       | 1.23±0.51                   | 1.21±0.45                      | 0.722   |
| TG (mM)                          | 1.96±1.12                   | 1.83±1.14                      | 0.628   |
| Previous treatments (n, %)       |                             |                                |         |
| Antihypertensive drugs           | 61 (55.45)                  | 70 (55.12)                     | 0.998   |
| Hypoglycemic drugs               | 19 (40.43)                  | 22 (42.31)                     | 0.998   |
| Statins                          | 29 (21.32)                  | 33 (20.89)                     | 0.998   |
| Antiplatelet drugs               | 41 (30.15)                  | 48 (30.38)                     | 0.998   |

MI, myocardial infarction; TC, total cholesterol; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; TG, triglycerides

The following values were used to evaluate the degree of stenosis: 50%–69% with peak systolic velocities of 120–220 cm/s and internal carotid artery/common carotid artery ratio of 1.5–3.7; and 70%–99% with peak systolic velocities of >220 cm/s and internal carotid artery/common carotid artery ratio of >3.7. To assess the measurement reproducibility of the degree of stenosis in the current study, for 28 randomly selected patients, the analyses of the degree of stenosis were performed twice using an investigator (Jie Li), and subsequently using another sonographer (Hong Chen), after which the consistency was determined. The coefficients of intra-observer and inter-observer variations for the degree of stenosis were 7.4% and 7.8%, respectively, suggesting relatively reliable measurements in the current study. One of the investigators (Jie Li) then assessed all patients. These duplex-based stenosis groups were also compared with 80 carotid arteries blindly measured on conventional angiographies according to North American Symptomatic Carotid Endarterectomy Trial (NASCET) criteria. Exact agreement was found in 85% of the cases, and there were no major (>1 stenosis group up or down) disagreements.

Genotyping

Eleven SNPs of seven CYP genes (Supplementary Table 1), including CYP2J2 (rs10889160), CYP2C8 (rs17110453, rs1934980), CYP2C9 (rs1799853, rs1057910), CYP3A5 (rs776746), EPHX2 (rs751141), CYP4F2 (rs3093135, rs2108622), and CYP4A11 (rs2269231, rs9333025), were selected according to the following criteria: (i) Minor allele frequency >0.05 (http://www.ncbi.nlm.nih.gov/SNP); (ii) nonsynonymous variants; (iii) SNPs that have been implicated in previous studies.

Whole blood (3 ml) collection, genomic DNA extraction, and genotyping were performed as previously described. Each assessed SNP was designed with two amplification primers and one extension primer (Supplementary Table 1).

Measurement of Plasma 20-HETE, EETs, and DiHETEs Levels

A blood sample (4 ml) was collected into EDTA/BHT (butylated hydroxytoluene)/glutathione at the second day after admission, and plasma was isolated following centrifugation and samples were stored at −80°C until analysis. CYP450 plasma metabolite levels were measured in 186 consecutive IS patients (90 patients with carotid stenosis and 96 patients without carotid stenosis) between August 2011 and March 2012. Plasma 20-HETE level was analyzed using a stable isotope dilution gas chromatography/mass spectrometry.
| rs10889160   | carotid stenosis (n = 136) | Non-carotid stenosis (n = 158) | P value | OR \(^1\) (95% CI) |
|--------------|----------------------------|---------------------------------|---------|---------------------|
| AA, n (%)    | 103 (75.74)                | 121 (76.58)                     | 0.826   | 0.96 (0.56-1.75)    |
| AG, n (%)    | 32 (23.52)                 | 35 (22.15)                      |         |                     |
| GG, n (%)    | 1 (0.74)                   | 2 (1.27)                        |         |                     |

| rs17110453   | carotid stenosis (n = 136) | Non-carotid stenosis (n = 158) | P value | OR \(^1\) (95% CI) |
|--------------|----------------------------|---------------------------------|---------|---------------------|
| AA, n (%)    | 52 (38.23)                 | 76 (48.10)                      |         |                     |
| AC, n (%)    | 49 (36.03)                 | 69 (43.67)                      |         |                     |
| CC, n (%)    | 35 (25.74)                 | 13 (8.23)                       | <0.001  | 2.28 (1.31-5.42)    |

| rs1934980    | carotid stenosis (n = 136) | Non-carotid stenosis (n = 158) | P value | OR \(^1\) (95% CI) |
|--------------|----------------------------|---------------------------------|---------|---------------------|
| CC, n (%)    | 21 (15.44)                 | 23 (14.56)                      |         |                     |
| CT, n (%)    | 61 (44.85)                 | 71 (44.93)                      |         |                     |
| TT, n (%)    | 54 (39.71)                 | 64 (40.51)                      | 0.894   | 1.03 (0.66-2.01)    |

| rs1799853    | carotid stenosis (n = 136) | Non-carotid stenosis (n = 158) | P value | OR \(^1\) (95% CI) |
|--------------|----------------------------|---------------------------------|---------|---------------------|
| CC, n (%)    | 136 (100)                  | 158 (100)                       | –       | –                   |

| rs1057910    | carotid stenosis (n = 136) | Non-carotid stenosis (n = 158) | P value | OR \(^1\) (95% CI) |
|--------------|----------------------------|---------------------------------|---------|---------------------|
| AA, n (%)    | 122 (89.71)                | 143 (90.51)                     |         |                     |
| AC, n (%)    | 12 (8.82)                  | 12 (7.59)                       |         |                     |
| CC, n (%)    | 2 (1.47)                   | 3 (1.90)                        | 0.768   | 1.06 (0.52-2.23)    |

| rs776746     | carotid stenosis (n = 136) | Non-carotid stenosis (n = 158) | P value | OR \(^1\) (95% CI) |
|--------------|----------------------------|---------------------------------|---------|---------------------|
| AA, n (%)    | 11 (8.09)                  | 24 (15.19)                      |         |                     |
| AG, n (%)    | 47 (34.56)                 | 65 (41.14)                      |         |                     |
| GG, n (%)    | 78 (57.35)                 | 69 (43.67)                      | 0.042   | 1.36 (0.98-3.75)    |

| rs751141     | carotid stenosis (n = 136) | Non-carotid stenosis (n = 158) | P value | OR \(^1\) (95% CI) |
|--------------|----------------------------|---------------------------------|---------|---------------------|
| GG, n (%)    | 99 (72.79)                 | 86 (54.43)                      | 0.007   | 3.01 (1.18-7.06)    |
| AG, n (%)    | 34 (25.00)                 | 65 (41.14)                      |         |                     |
| AA, n (%)    | 3 (2.21)                   | 7 (4.43)                        |         |                     |

| rs2269231    | carotid stenosis (n = 136) | Non-carotid stenosis (n = 158) | P value | OR \(^1\) (95% CI) |
|--------------|----------------------------|---------------------------------|---------|---------------------|
| AA, n (%)    | 28 (20.59)                 | 28 (17.72)                      |         |                     |
| AT, n (%)    | 73 (53.68)                 | 86 (54.43)                      |         |                     |
| TT, n (%)    | 35 (25.73)                 | 44 (27.85)                      | 0.658   | 0.95 (0.52-1.89)    |

| rs9333025    | carotid stenosis (n = 136) | Non-carotid stenosis (n = 158) | P value | OR \(^1\) (95% CI) |
|--------------|----------------------------|---------------------------------|---------|---------------------|
| AA, n (%)    | 2 (1.47)                   | 4 (2.53)                        |         |                     |
| AG, n (%)    | 22 (16.18)                 | 51 (32.28)                      |         |                     |
| GG, n (%)    | 112 (82.35)                | 103 (65.19)                     | 0.006   | 1.97 (1.22-6.16)    |

| rs3093135    | carotid stenosis (n = 136) | Non-carotid stenosis (n = 158) | P value | OR \(^1\) (95% CI) |
|--------------|----------------------------|---------------------------------|---------|---------------------|
| TT, n (%)    | 115 (84.56)                | 129 (81.65)                     |         |                     |
| AT, n (%)    | 19 (13.97)                 | 25 (15.82)                      |         |                     |
| AA, n (%)    | 2 (1.47)                   | 4 (2.53)                        | 0.766   | 1.01 (0.51-2.12)    |

| rs2108622    | carotid stenosis (n = 136) | Non-carotid stenosis (n = 158) | P value | OR \(^1\) (95% CI) |
|--------------|----------------------------|---------------------------------|---------|---------------------|
| GG, n (%)    | 74 (54.41)                 | 78 (49.37)                      |         |                     |
| GA, n (%)    | 51 (37.50)                 | 66 (41.77)                      |         |                     |
| AA, n (%)    | 11 (8.09)                  | 14 (8.86)                       | 0.392   | 0.98 (0.48-1.96)    |

OR, odds ratio; CI, confidence interval.
\(^1\)OR adjusted for age, gender, hypertension, diabetes, smoking and hypercholesterolemia.
Plasma 20-HETE, EETs, and DiHETEs levels were measured using a stable isotope dilution GC/MS following base hydrolysis and separation on high-performance liquid chromatography (HPLC), as previously described.12

Statistical Analysis

For quantitative and qualitative demographic and clinical variables, the Student’s t-test and χ²-test were performed, respectively. Hardy–Weinberg equilibrium was evaluated using the χ²-test. Differences of genotypes were determined using the χ²-test, and levels of plasma 20-HETE, EETs, and DiHETEs were compared using the Student’s t-test. Analysis of variance (ANOVA) followed by the Student–Newman–Keuls test was employed to evaluate differences of plasma 20-HETE, EETs, and DiHETEs levels between patients with carotid stenosis and patients without carotid stenosis stratified by genotypes. Multivariate logistic regression analyses accounting for potential confounders of age, gender, hypertension, diabetes, smoking, and hypercholesterolemia were conducted to estimate the associations between assessed variants and carotid stenosis risk. For associations reaching $P=0.05$ threshold, a Bonferroni correction was conducted to account for multiple comparison issues.22, 23 Specifically, a threshold of $0.05/7=0.0071$ was used because 11 variants from 7 genes were tested. All statistical analyses were performed using SPSS 16.0 (SPSS Inc., Chicago, IL, USA).

Gene–gene interactions were investigated using the statistical software program generalized multifactor dimensionality reduction (GMDR) Beta, version 0.7 (www.healthsystem.virginia.edu/internet/addiction-genomics/Software).13, 24 Plasma 20-HETE, EETs, and DiHETEs levels identified significantly associated variants and variant interactions, as well as hypertension and diabetes mellitus were jointly incorporated in a multi-variable regression model to assess whether the associations with carotid stenosis remain after controlling for other factors.

Results

Patient Characteristics

There were no significant differences between patients with or without carotid stenosis in terms of demographic and clinical characteristics (all $P>0.05$; Table 1).

Genotype Distributions in Patients with or without Carotid Stenosis

The genotype distributions of the 11 variants in patients without carotid stenosis were consistent with the Hardy–Weinberg Equilibrium (all $P>0.05$). Frequencies of rs17110453CC, rs776746GG, rs751141GG, and rs9333025GG genotypes were significantly higher in patients with carotid stenosis than patients without carotid stenosis (Table 2). After adjusting for potential confounding variables of age, gender, hypertension, diabetes, smoking, and hypercholesterolemia, CC, GG, and GG genotypes of rs17110453, rs751141, and rs9333025 were significantly associated with the risk of carotid stenosis (OR = 2.28, 95% CI: 1.31 – 5.42, $P < 0.001$; OR = 3.01, 95% CI: 1.18 – 7.06, $P = 0.007$; and

Table 3. Comparison of the best models, prediction accuracies, cross-validation consistencies, and $P$ values identified by GMDR

| Best model* | Training Balanced Accuracy | Testing Balanced Accuracy | Cross-validation consistency | Sign test (P) |
|-------------|---------------------------|--------------------------|-----------------------------|--------------|
| 1           | 0.5124                    | 0.5115                   | 9/10                        | 7 (0.1726)   |
| 1, 2        | 0.5685                    | 0.5418                   | 10/10                       | 9 (0.0116)   |
| 1, 2, 3     | 0.5422                    | 0.5211                   | 7/10                        | 8 (0.2566)   |
| 1, 2, 3, 4  | 0.5691                    | 0.6188                   | 5/10                        | 7 (0.5264)   |
| 1, 2, 3, 4, 5| 0.6236                   | 0.5217                   | 10/10                       | 9 (0.6326)   |
| 1, 2, 3, 4, 5, 6| 0.6124               | 0.4988                   | 8/10                        | 5 (0.7235)   |
| 1, 2, 3, 4, 5, 6, 7| 0.6328              | 0.4946                   | 6/10                        | 3 (0.8233)   |
| 1, 2, 3, 4, 5, 6, 7, 8| 0.6422             | 0.5123                   | 8/10                        | 5 (0.2367)   |
| 1, 2, 3, 4, 5, 6, 7, 8, 9| 0.6527          | 0.5011                   | 7/10                        | 6 (0.9112)   |
| 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 | 0.6625 | 0.5133 | 6/10 | 5 (0.6357) |
| 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 | 0.6472 | 0.5311 | 7/10 | 4 (0.4336) |

*rs17110453, rs9333025, rs751141, rs1934980, rs10889160, rs1057910, rs776746, rs1799853, rs3093135, rs2269231, rs2108622 are symbolized as 1–11, respectively.

GMDR, generalized multifactor dimensionality reduction.
OR = 1.97, 95% CI: 1.22–6.16, P = 0.006; respectively, Table 2), after correcting for multiple comparisons.

**Gene–Gene Interactions in Mediating the Risk of Carotid Stenosis**

Significant high-order interactions were detected for the association with carotid stenosis risk (Table 3). With covariates adjustment, the best model indicated an interaction between rs17110453 and rs9333025, which scored 10/10 for cross-validation consistency and 9/10 for the sign test (P = 0.0116), suggesting a synergistic effect of the two variants in mediating the risk of carotid stenosis.

**Different Genotype Combinations of rs17110453 and rs9333025 in Affecting the Risk of Carotid Stenosis**

Supplementary Table 2 shows associations between carotid stenosis risk and the nine different genotype combinations of rs17110453 and rs9333025 compared with the reference genotype combination of rs17110453AA and rs9333025AA. Two interactions conferring increased phenotype risks were rs17110453CC, rs9333025GG and rs17110453CC, rs9333025AG. The estimated risk of carotid stenosis was significantly higher compared with the reference genotype combination of genotype combinations of rs17110453 and rs9333025, indicating an interaction between rs17110453 and rs9333025, which scored 10/10 for cross-validation consistency and 9/10 for the sign test (P = 0.0116), suggesting a synergistic effect of the two variants in mediating the risk of carotid stenosis.

**CYP Plasma Metabolite Levels with Carotid Stenosis and Their Relationship with CYP Genetic Variants**

Plasma levels of 20-HETE and DiHETEs were significantly higher in patients with carotid stenosis compared with those in patients without carotid stenosis; and EETs levels were significantly lower in patients with carotid stenosis (all P < 0.001, Table 4). Stratified analyses based on different genotypes of the three identified variants revealed that the identified significant differences existed in the strata of specific genotypes. Particularly, carotid stenosis patients carrying the rs9333025GG genotype had higher 20-HETE levels than patients without carotid stenosis who carried the rs9333025GG genotype; carotid stenosis patients carrying the rs17110453CC genotype had lower plasma EETs levels than patients without carotid stenosis who carried the same genotype; and carotid stenosis patients carrying the rs751141GG genotype had lower plasma levels of EETs and higher plasma levels of DiHETEs compared with those in patients without carotid stenosis who carried the rs751141GG genotype (all P < 0.01, Table 5). When focusing on patients with carotid stenosis, individuals with the genotype of GG for rs9333025 tended to have higher 20-HETE levels than individuals with other two genotypes for this variant (1833 ± 187 vs 1623 ± 171; P < 0.001); individuals with the genotype of CC for rs17110453 tended to have lower EETs levels than individuals with other two genotypes for this variant (58.72 ± 5.63 vs 63.74 ± 5.54; P < 0.001); individuals with genotype of GG for rs751141 tended to have lower EETs levels and higher DiHETEs levels than individuals with other two genotypes for this variant (58.24 ± 4.67 vs 63.14 ± 5.62; P < 0.001; and 106.24 ± 11.22 vs 74.58 ± 5.96; P < 0.001, respectively).

Logistic regression analysis indicated that rs751141GG was independently associated with low EETs (OR = 1.72, 95% CI 1.04–3.82, P = 0.021), also the genotype combination of rs17110453CC and rs9333025GG was independently associated with high 20-HETE (OR = 1.96, 95% CI 1.17–3.56, P = 0.004), high DiHETEs (OR = 1.87, 95% CI 1.21–5.42, P = 0.005) and low EETs (OR = 2.11, 95% CI 1.34–6.29, P = 0.001), after adjusting for diabetes mellitus and hypertension. It was also shown that high 20-HETE, high DiHETEs, and low EETs were independent risk factors for carotid stenosis, after adjusting for hypertension, diabetes mellitus, rs751141GG, and the genotype combination of rs17110453CC and rs9333025GG (Table 6).
symptomatic carotid stenosis. Research has shown that 20-HETE and DiHETEs were significantly lower in patients with carotid stenosis in IS patients. We detected that the association between CYP450 genetic polymorphisms, CYP pathway genes and carotid stenosis, as well as the potential effects of these variants on mediating the differences of CYP450 metabolite levels in patients with carotid stenosis versus those without. A previous study has shown that a functional variant in CYP4A11 is associated with 20-HETE levels and essential hypertension. Our data indicated that the rs9333025GG genotype might be associated with a higher 20-HETE level, which might partially explain its association with a higher risk of carotid stenosis. Additionally, the rs17110453CC genotype is associated with a lower EETs level, and the rs751141GG genotype is associated with a lower level of EETs and a higher level of DiHETEs. These results indicate that CYP450 polymorphisms can influence AA metabolism enzymes and further alter 20-HETE, EETs, and DiHETEs levels, which eventually affect the risk of carotid stenosis.

Besides these important findings, we detected gene–gene interaction in mediating metabolite levels and disease risk. Variants rs17110453 and rs9333025 were identified to interact together to influence the risk of carotid stenosis. Compared with the reference genotype combination of rs17110453AA and rs9333025AA, there was a 2.06-fold increased risk for carotid stenosis in individuals with a combined geno-

| Carotid stenosis (n = 90) | Non-carotid stenosis (n = 96) |  | Carotid stenosis (n = 90) | Non-carotid stenosis (n = 96) |  | Carotid stenosis (n = 90) | Non-carotid stenosis (n = 96) |  |
|--------------------------|-------------------------------|---|--------------------------|-------------------------------|---|--------------------------|-------------------------------|---|
| rs17110453               |                               |   | rs751141                 |                               |   | rs9333025                |                               |   |
| AA                       | 1682 ± 186                    | 1668 ± 180                  | 83.13 ± 6.15                | 79.18 ± 7.14                 | 0.55 | 63.80 ± 6.11             | 64.66 ± 5.53                 | 0.01 |
| AC                       | 1656 ± 181                    | 1698 ± 182                  | 83.35 ± 10.72               | 81.68 ± 7.22                 | 0.14 | 63.67 ± 5.14             | 63.11 ± 6.21                 | 0.01 |
| CC                       | 1748 ± 193                    | 1699 ± 191                  | 83.12 ± 10.24               | 81.87 ± 6.13                 | 58.72 ± 5.63             | 70.23 ± 6.55             | < 0.01 |
| rs9333025                |                               |                            | 106.24 ± 11.22              | 78.24 ± 6.37                 | 0.22 | 71.88 ± 4.66             | 70.78 ± 5.22                 | 0.42 |
| AA                       | 1602 ± 177                    | 1567 ± 176                  | 82.12 ± 8.51                | 79.36 ± 9.28                 | 0.32 | 61.11 ± 5.67             | 62.68 ± 6.82                 | 0.01 |
| AG                       | 1646 ± 161                    | 1620 ± 171                  | 85.89 ± 9.12                | 83.98 ± 8.76                 | 0.14 | 61.89 ± 6.17             | 63.04 ± 6.35                 | 0.78 |
| GG                       | 1833 ± 187                    | 1635 ± 168                  | 83.87 ± 8.02                | 81.88 ± 7.01                 | 0.01 | 60.78 ± 5.66             | 61.92 ± 6.91                 | 0.01 |

*Statistical significance was based on analysis of variance.
HETE, hydroxyeicosatetraenoic acid; EET, epoxyeicosatrienoic acids; DiHETE, dihydroxyeicosatrienoic acid.

**Discussion**

In the present study we investigated the relationship between CYP450 genetic polymorphisms, CYP plasma metabolite levels, and the risk of symptomatic carotid stenosis in IS patients. We detected that 20-HETE and DiHETEs were significantly higher and EETs were significantly lower in patients with symptomatic carotid stenosis. Research has shown that 20-HETE can constrict cerebral arteries and is involved in endothelial dysfunction. EETs have vascular relaxation effects and play protective roles in the cardiovascular system. EETs can be metabolized by sEH to yield less biologically active DiHETEs. The pharmacological inhibition or genetic deletion of sEH has been shown to increase EETs levels and protect from stroke-induced brain injury. This protective effect of EETs has also been demonstrated in an animal model. Overall, it is plausible that altered 20-HETE, EETs, and DiHETEs levels could contribute to carotid stenosis or IS onset.

Our data revealed that genotypes of rs17110453CC, rs751141GG, and rs9333025GG were significantly associated with the risk of carotid stenosis in IS patients. Additionally, these genetic variants might affect CYP450 metabolite levels in IS patients with carotid stenosis versus those without. A number of studies have explored the association of CYP450 genes with blood pressure and IS. Some studies have also shown that CYP450 plasma metabolite levels are associated with IS risk. To the best of our knowledge, this is the first study to investigate the association between the genetic variations of CYP pathway genes and carotid stenosis, as well as the potential effects of these variants on mediating the differences of CYP450 metabolite levels in patients with carotid stenosis versus those without.
cate that patients with carotid stenosis usually show higher frequencies of elderly population, hypertension, cigarette smoking, dyslipidemia, diabetes, and ischemic heart disease than those seen in patients with no carotid stenosis. However, there were no significant differences of these relevant factors between patients with and without carotid stenosis in our study sample. There may be certain biases involved in sample selection in our study. Furthermore, the carotid plaque morphological characters such as echolucent plaque and ulcerative plaque were strong risk factors for IS and it would be interesting to explore their association with CYP genetic variants and AA metabolites levels. This research question, however, is beyond the scope and focus of the current study, and we will work on this research question in our future study.

### Conclusion

In conclusion, we identified that variants rs17110453 and rs9333025 were significantly associated with carotid stenosis risk. Furthermore, these polymorphisms were associated with CYP plasma metabolite levels in patients with carotid stenosis. There was a significant gene–gene interaction between rs17110453 and rs9333025 in affecting the risk of carotid stenosis. Overall, specific CYP450 gene SNPs and their interactions are associated with CYP450 plasma metabolite levels, which may partially explain their associations with carotid stenosis risk. Further studies are needed to validate our findings.

### Funding

This study was supported by grants from the Scientific Research Foundation of Sichuan Provincial Health Department (#140025) and Deyang City Science and Technology Research Foundation (#2014SZ035).
Conflicts of Interest

None.

References

1) O’Leary DH, Polak JF, Kronmal RA, Kittner SJ, Bond MG, Wolfson SK, Jr., Bommer W, Price TR, Gardin JM and Savage PJ: DHS Collaborative Research Group. Stroke, 1992; 23: 1752-1760

2) Inzitari D, Eliasziw M, Gates P, Sharpe BL, Chan RK, Meldrum HE and Barnett HJ: The causes and risk of stroke in patients with asymptomatic internal-carotid-artery stenosis. North American Symptomatic Carotid Endarterectomy Trial Collaborators. N Engl J Med, 2000; 342: 1693-1700

3) Zhu CZ and Norris JW: Role of carotid stenosis in ischemic stroke. Stroke, 1990; 21: 1131-1134

4) Rothwell PM, Eliasziw M, Gutnikov SA, Warlow CP and European Carotid Surgery Trialist’s C: Reanalysis of the final results of the randomised controlled trials of endarterectomy for symptomatic carotid stenosis. Lancet, 2003; 361: 107-116

5) Brott TG, Hobson RW, Howard G, Roubin GS, Clark WM, Brooks W, Mackey A, Hill MD, Leimgruber PP, Sheffet AJ, Howard VJ, Moore WS, Voeks JH, Hopkins LN, Cutlip DE, Cohen DJ, Popma J, Ferguson RD, Cohen SN, Blackshear JL, Silver FL, Mohr JP, Lal BK, Meschia JF and Investigators C: Stenting versus endarterectomy for treatment of carotid-artery stenosis. N Engl J Med, 2010; 363: 11-23

6) Barnett HJ, Taylor DW, Eliasziw M, Fox AJ, Ferguson GG, Haynes RB, Rankin RN, Clagett GP, Hachinski VC, Sackett DL, Thorpe KE, Meldrum HE and Spence JD: Benefit of carotid endarterectomy in patients with symptomatic moderate or severe stenosis. North American Symptomatic Carotid Endarterectomy Trial Collaborators. N Engl J Med, 1998; 339: 1415-1425

7) Gardener H, Beecham A, Cabral D, Yanuck D, Slifer S, Wang L, Blanton SH, Sacco RL, Juvic SH and Rundek T: Carotid plaque and candidate genes related to inflammation and endothelial dysfunction in Hispanics from northern Manhattan. Stroke, 2011; 42: 889-896

8) Reinhard W, Stark K, Sedlacek K, Fischer M, Baessler A, Neureuther K, Weber S, Kessler W, Wieldmann S, Mitschke S, Lieb W and Trabert K: The causes and risk of stroke in patients with asymptomatic internal-carotid-artery stenosis. North American Symptomatic Carotid Endarterectomy Trial Collaborators. N Engl J Med, 2000; 342: 1693-1700

9) Calder PC: Polysaturated fatty acids and inflammatory processes: New twists in an old tale. Biochimie, 2009; 91: 791-795

10) Lasker JM, Chen WB, Wolf I, Bloswick BP, Wilson PD and Powell PK: Formation of 20-hydroxyeicosatetraenoic acid, a vasoactive and natriuretic eicosanoid, in human kidney. Role of Cyp4F2 and Cyp4A11. J Biol Chem, 2000; 275: 4118-4126

11) Zeldin DC: Epoxygenase pathways of arachidonic acid metabolism. J Biol Chem, 2001; 276: 36059-36062

12) Ward NC, Croft KD, Blacker D, Hankey GJ, Barden A, Mori TA, Puddley IB and Beer CD: Cytochrome P450 metabolites of arachidonic acid are elevated in stroke patients compared with healthy controls. Clin Sci (Lond), 2011; 121: 501-507

13) Chi LF, Yi XY, Shao MJ, Lin J and Zhou Q: Interaction between ALOX5AP and CYP3A5 gene variants significantly increases the risk for cerebral infarctions in Chinese. Neuroreport, 2014; 25: 452-457

14) Ding H, Cui G, Zhang L, Xu Y, Bao X, Yu Y, Wu B, Wang Q, Hui R, Wang W, Dackor RT, Kissling GE, Zeldin DC and Wang DW: Association of common variants in CYP4A11 and CYP4F2 with stroke in the Han Chinese population. Pharmacogenom Genomics, 2010; 20: 187-194

15) Munshi A, Sharma V, Kaul S, Al-Hazzani A, Alsharawi AA, Shafi G, Koppula R, Mallemogollala SB and Jyothy A: Association of 1347 G/A cytochrome P450 4F2 (CYP4F2) gene variant with hypertension and stroke. Mol Biol Rep, 2012; 39: 1677-1682

16) Fava C, Montagnana M, Almgren P, Rosberg L, Lippi G, Hedblad B, Engstrom G, Berglund M, Minuz P and Melander O: The V433M variant of the CYP4F2 is associated with ischemic stroke in male Swedes beyond its effect on blood pressure. Hypertension, 2008; 52: 373-380

17) Yi X, Liao D, Fu X, Zhang B and Wang C: Interaction among CYP2C8, EPHX2, and CYP4A11 Gene Variants Significantly Increases the Risk for Ischemic Stroke in Chinese Populations. J Atheroscler Thromb, 2015;

18) Kaikita K, Ono T, Iwashita S, Nakayama N, Sato K, Horio E, Nakamura S, Tsuji K, Tayama S, Hokimoto S, Sakamoto T, Nakao K, Oshima S, Sugiyama S and Ogawa H: Impact of CYP2C19 polymorphism on platelet function tests and coagulation and inflammatory biomarkers in patients undergoing percutaneous coronary intervention. J Atheroscler Thromb, 2014; 21: 64-76

19) Worrall BB, Ahsar S, Nyquist PA, Ackerman RH, Hamm TL and DeGraba TJ: Interleukin-1 receptor antagonist gene polymorphisms in carotid atherosclerosis. Stroke, 2003; 34: 790-793

20) Momjian-Mayor I, Kuzmanovic I, Momjian S, Bonvicin A, Albanese S, Bichsel D, Comelli M, Pereira VM, Lovblad KO and Sztajzel RF: Accuracy of a novel risk index combining degree of stenosis of the carotid artery and plaque surface echogenicity. Stroke, 2012; 43: 1260-1265

21) Rothwell PM, Gutnikov SA, Warlow CP and European Carotid Surgery Trialist’s C: Reanalysis of the final results of the European Carotid Surgery Trial. Stroke, 2003; 34: 514-523

22) Wu L, Rabe KG and Petersen GM: Do variants associated with susceptibility to pancreatic cancer and type 2 diabetes reciprocally affect risk? PLoS one, 2015; 10: e0117230

23) Wu L, Goldstein AM, Yu K, Yang XR, Rabe KG, Arslan AA, Canzian F, Wolpin BM, Stolzenberg-Solomon R, Amundadottir LT and Petersen GM: Variants associated with susceptibility to pancreatic cancer and melanoma do not reciprocally affect risk. Cancer epidemiology, bio-
markers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2014; 23: 1121-1124

24) Lou XY, Chen GB, Yan L, Ma JZ, Zhu J, Elston RC and Li MD: A generalized combinatorial approach for detecting gene-by-gene and gene-by-environment interactions with application to nicotine dependence. Am J Hum Genet, 2007; 80: 1125-1137

25) Gladden MH, Jankowska E and Czarkowska-Bauch J: New observations on coupling between group II muscle afferents and feline gamma-motoneurones. J Physiol, 1998; 512 (Pt 2): 507-520

26) Singh H, Cheng J, Deng H, Kemp R, Ishizuka T, Nasjletti A and Schwartzman ML: Vascular cytochrome P450 4A expression and 20-hydroxyeicosatetraenoic acid synthesis contribute to endothelial dysfunction in androgen-induced hypertension. Hypertension, 2007; 50: 123-129

27) Larsen BT, Gutterman DD and Hatoum OA: Emerging role of epoxyeicosatrienoic acids in coronary vascular function. Eur J Clin Invest, 2006; 36: 293-300

28) Iliff JJ, Close LN, Selden NR and Alkayed NJ: A novel role for P450 eicosanoids in the neurogenic control of cerebral blood flow in the rat. Exp Physiol, 2007; 92: 653-658

29) Liu M and Alkayed NJ: Hypoxic preconditioning and tolerance via hypoxia inducible factor (HIF) 1alpha-linked induction of P450 2C11 epoxygenase in astrocytes. J Cereb Blood Flow Metab, 2005; 25: 939-948

30) Gainer JV, Bellamine A, Dawson EP, Womble KE, Grant SW, Wang Y, Cupples LA, Guo CY, Demissie S, O'Donnell CJ, Brown NJ, Waterman MR and Capdevila JH: Functional variant of CYP4A11 20-hydroxyeicosatetraenoic acid synthase is associated with essential hypertension. Circulation, 2005; 111: 63-69

31) Deng Y, Edin ML, Theken KN, Schuck RN, Flake GP, Kannon MA, DeGraff LM, Lib FB, Foley J, Bradbury JA, Graves JP, Tomer KB, Falck JR, Zeldin DC and Lee CR: Endothelial CYP epoxygenase overexpression and soluble epoxide hydrolase disruption attenuate acute vascular inflammatory responses in mice. FASEB J, 2011; 25: 703-713

32) Tanaka Y, Omura T, Fukasawa M, Horiuchi N, Miyata N, Minagawa T, Yoshida S and Nakaie S: Continuous inhibition of 20-HETE synthesis by TS-011 improves neurological and functional outcomes after transient focal cerebral ischemia in rats. Neurosci Res, 2007; 59: 475-480

33) Gronholdt ML, Nordestgaard BG, Schroeder TV, Vorstrup S and Sillesen H: Ultrasonic echolucent carotid plaques predict future strokes. Circulation, 2001; 104: 68-73
**Supplementary Table 1.** Amplification and extension primers

| SNPs          | Forward primer and Reverse primer (5′→3′)                                                                 | Extension primer (5′→3′)                       |
|---------------|-----------------------------------------------------------------------------------------------------------|-----------------------------------------------|
| **CYP2J2**    | F: CGTTGGATGGGATAATGAGAGGAGTTGC R: ACCTTGGATGGTACATCATCATGAGATTC | AAGGGGAGAAATTCAACTTTTGTG                      |
| **CYP2G8**    | F: ACCTTGGATGGCAGACTGATTGTGGGAGTGC R: ACCTTGGATGGTACATCATCATGAGATTC | CTTTCCCCTCAGGTCAAA                           |
| **CYP2G8**    | F: ACCTTGGATGGGATAATGAGAGGAGTTGC R: ACCTTGGATGGTACATCATCATGAGATTC | GAGGACATTTGAGAC                             |
| **CYP2G9**    | F: ACCTTGGATGGGATAATGAGAGGAGTTGC R: ACCTTGGATGGTACATCATCATGAGATTC | CACGGAGCCAGAGATAC                           |
| **CYP3A5**    | F: ACCTTGGATGGGATAATGAGAGGAGTTGC R: ACCTTGGATGGTACATCATCATGAGATTC | CCAACACGGGAGAGATA                           |
| **EPHX2**     | F: ACCTTGGATGGGATAATGAGAGGAGTTGC R: ACCTTGGATGGTACATCATCATGAGATTC | CCCAGGCAGGTCTCC                           |
| **CYP4F2**    | F: ACCTTGGATGGGATAATGAGAGGAGTTGC R: ACCTTGGATGGTACATCATCATGAGATTC | CATATAACAGCAGCTAGAG                      |
| **CYP4F2**    | F: ACCTTGGATGGGATAATGAGAGGAGTTGC R: ACCTTGGATGGTACATCATCATGAGATTC | CCAATTCATGAAGCA                             |
| **CYP4A11**   | F: ACCTTGGATGGGATAATGAGAGGAGTTGC R: ACCTTGGATGGTACATCATCATGAGATTC | TCCTGTTTTTTCCTCTAGC                         |
| **CYP4A11**   | F: ACCTTGGATGGGATAATGAGAGGAGTTGC R: ACCTTGGATGGTACATCATCATGAGATTC | GCTCAAGGCTAAGGTGAC                         |

SNPs, single nucleotide polymorphisms; F, forward primer; R, reverse primer.

**Supplementary Table 2.** Associations between carotid stenosis and different combinations of genotypes

| rs17110453  | AA | CC | AC | CC | AC | CC | AA | AA | AC |
|-------------|----|----|----|----|----|----|----|----|----|
| rs933025    | AA | GG | GG | AG | AG | AA | AG | GG | AA |
| OR          | 1* | 2.06 | 1.21 | 1.93 | 1.06 | 1.02 | 0.95 | 1.01 | 0.98 |
| 95% CI      | –  | 1.11−7.25 | 0.62−2.24 | 1.00−5.42 | 0.72−2.11 | 0.60−1.64 | 0.48−1.52 | 0.73−1.81 | 0.57−1.59 |
| P value     | –  | 0.014 | 0.286 | 0.041 | 0.524 | 0.718 | 0.821 | 0.682 | 0.792 |

*Non-risk genotype for each genetic factor was used as the reference OR. OR, odds ratios.